Motley Fool5d agobullish
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?The next six months may be decisive for the biotech.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
531last 24h
2507last 7d
477● bullish (7d)
255● bearish (7d)
197publishers
